{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:46:42Z","timestamp":1783050402770,"version":"3.54.6"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Anti-Infective Research and Development"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the genotypic and ceftazidime\/avibactam-susceptibility profiles amongst ceftolozane\/tazobactam-non-susceptible (NS), MBL-negative Pseudomonas aeruginosa in a global surveillance programme.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Isolates were collected as part of the ERACE-PA Global Surveillance programme. Carbapenem-resistant P. aeruginosa deemed clinically relevant by the submitting laboratories were included. Broth microdilution MICs were conducted per CLSI standards to ceftolozane\/tazobactam, ceftazidime\/avibactam, ceftazidime and cefepime. Genotypic carbapenemases were detected using CarbaR and CarbaR NxG (research use only). Isolates negative for carbapenemases by PCR were assessed via WGS. Isolates were included in the analysis if they were ceftolozane\/tazobactam-NS and lacked detection of known MBLs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 807 isolates collected in the ERACE-PA programme, 126 (16%) were ceftolozane\/tazobactam-NS and lacked MBLs. Cross-resistance to ceftazidime and cefepime was common, with only 5% and 16% testing susceptible, respectively. Ceftazidime\/avibactam retained in vitro activity, with 65% of isolates testing susceptible. GES was the most common enzymology, detected in 57 (45%) isolates, and 89% remained susceptible to ceftazidime\/avibactam. Seven isolates harboured KPC and all tested susceptible to ceftazidime\/avibactam. In the remaining 62 isolates, WGS revealed various ESBLs or OXA \u03b2-lactamases. While 39% remained susceptible to ceftazidime\/avibactam, marked variability was observed among the diverse resistance mechanisms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ceftazidime\/avibactam remained active in vitro against the majority of ceftolozane\/tazobactam-NS, MBL-negative P. aeruginosa. Ceftazidime\/avibactam was highly active against isolates harbouring GES and KPC \u03b2-lactamases. These data highlight the potential clinical utility of genotypic profiling as well as the need to test multiple novel agents when carbapenem-resistant P. aeruginosa are encountered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac385","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T03:35:16Z","timestamp":1669088116000},"page":"252-256","source":"Crossref","is-referenced-by-count":16,"title":["Phenotypic and genotypic profile of ceftolozane\/tazobactam-non-susceptible, carbapenem-resistant <i>Pseudomonas aeruginosa<\/i>"],"prefix":"10.1093","volume":"78","author":[{"given":"Christian M","family":"Gill","sequence":"first","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-3263","authenticated-orcid":false,"given":"David P","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, CT , USA"},{"name":"Division of Infectious Diseases, Hartford Hospital , Hartford, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ERACE-PA Global Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadha","family":"Alfouzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Bourassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carey-Ann D","family":"Burnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Canton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Carmeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Kiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyros","family":"Pournaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Satlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrar K","family":"Thabit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Virginia","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Wille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais Teles Freitas","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhal","family":"Cekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulsah","family":"Malkocoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e8e","family":"Gij\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Layla Abdullah","family":"Tarakmeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Yat","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffel Johannes","family":"Opperman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsah Deepa","family":"Tootla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Moodley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Coetzee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Vourli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalya M","family":"Attallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Leonildi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesira","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Barnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Menichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Pilato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Codda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Westblade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferric","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"key":"2024021703025096800_dkac385-B1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/cid\/ciab295","article-title":"Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024021703025096800_dkac385-B2","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","article-title":"The ERACE-PA Global Surveillance Program: ceftolozane\/tazobactam and ceftazidime\/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas aeruginosa","volume":"40","author":"Gill","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2024021703025096800_dkac385-B3","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00189-22","article-title":"In vitro activity of ceftolozane-tazobactam, imipenem-relebactam, ceftazidime-avibactam, and comparators against Pseudomonas aeruginosa isolates collected in United States hospitals according to results from the SMART Surveillance Program, 2018 to 2020","volume":"66","author":"Karlowsky","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2024021703025096800_dkac385-B4","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.01026-20","article-title":"Ceftolozane\/tazobactam resistance and mechanisms in carbapenem-nonsusceptible Pseudomonas aeruginosa","volume":"6","author":"Teo","year":"2021","journal-title":"mSphere"},{"key":"2024021703025096800_dkac385-B5","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1093\/jac\/dkz149","article-title":"ESBLs and resistance to ceftazidime\/avibactam and ceftolozane\/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa","volume":"74","author":"de la Rosa","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024021703025096800_dkac385-B6","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014 Thirty-First Edition: M100","author":"CLSI","year":"2021"},{"key":"2024021703025096800_dkac385-B7","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.02015-19","article-title":"Evaluation of the EDTA-modified carbapenem inactivation method for detecting metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa","volume":"58","author":"Gill","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2024021703025096800_dkac385-B8","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01098-20","article-title":"Evaluation of the Xpert Carba-R NxG assay for detection of carbapenemase genes in a global challenge set of Pseudomonas aeruginosa isolates","volume":"58","author":"Gill","year":"2020","journal-title":"J Clin Microbiol"},{"key":"2024021703025096800_dkac385-B9","article-title":"In vitro activity of cefepime-taniborbactam against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain","volume":"66","author":"Hern\u00e1ndez-Garc\u00eda","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024021703025096800_dkac385-B10","article-title":"Evaluation of a modified carbapenem inactivation method for detection of carbapenemases in Pseudomonas aeruginosa","volume":"56","author":"Lisboa","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2024021703025096800_dkac385-B11","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2174\/1389450117666160310144501","article-title":"Structural and functional aspects of class A carbapenemases","volume":"17","author":"Naas","year":"2016","journal-title":"Curr Drug Targets"},{"key":"2024021703025096800_dkac385-B12","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing Pseudomonas aeruginosa\u2014an emerging challenge","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"2024021703025096800_dkac385-B13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00986-21","article-title":"In vivo evolution of GES \u03b2-lactamases driven by ceftazidime\/avibactam treatment of Pseudomonas aeruginosa infections","volume":"65","author":"Fraile-Ribot","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024021703025096800_dkac385-B14","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.cmi.2021.05.011","article-title":"Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis","volume":"27","author":"Cortes-Lara","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2024021703025096800_dkac385-B15","doi-asserted-by":"crossref","DOI":"10.1093\/femsle\/fnx161","article-title":"Comparative genomics of a drug-resistant Pseudomonas aeruginosa panel and the challenges of antimicrobial resistance prediction from genomes","volume":"364","author":"Jeukens","year":"2017","journal-title":"FEMS Microbiol Lett"},{"key":"2024021703025096800_dkac385-B16","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/jac\/dkaa513","article-title":"Class D \u03b2-lactamases","volume":"76","author":"Yoon","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024021703025096800_dkac385-B17","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1093\/jac\/dkac232","article-title":"In vivo translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime\/avibactam and meropenem against Pseudomonas aeruginosa","volume":"77","author":"Gill","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024021703025096800_dkac385-B18","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/252\/56679693\/dkac385.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/252\/56679693\/dkac385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T03:03:43Z","timestamp":1708139023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/1\/252\/6835807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,11,22]]},"published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac385","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,5]]},"published":{"date-parts":[[2022,11,22]]}}}